Lyell Immunopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated March 12, 2026, reports the issuance of a press release by Lyell Immunopharma, Inc. regarding its financial results for the quarter and full year ended December 31, 2025. The Company is incorporated in Delaware and trades on the NASDAQ Global Select Market under the symbol LYEL.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is referenced but not included in the provided text.
Material Changes
The filing text does not provide data to compare current period results against prior comparable periods. No specific material changes are detailed in the body of this 8-K.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document serves solely as a notification that the press release containing this information has been issued.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q4 and full-year 2025 financial figures.
- Verify the Company's cash position and runway based on the detailed results in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the press release includes updated financial guidance for 2026.